title: Neutralisation of HIV-1 cell-cell spread by human and llama antibodies.
abstract: BACKGROUND
  Direct cell-cell spread of HIV-1 is a very efficient mode of viral dissemination, with increasing evidence suggesting that it may pose a considerable challenge to controlling viral replication in vivo. Much current vaccine research involves the study of broadly neutralising antibodies (bNabs) that arise during natural infection with the aims of eliciting such antibodies by vaccination or incorporating them into novel therapeutics. However, whether cell-cell spread of HIV-1 can be effectively targeted by bNabs remains unclear, and there is much interest in identifying antibodies capable of efficiently neutralising virus transmitted by cell-cell contact.
  
  
  RESULTS
  In this study we have tested a panel of bNAbs for inhibition of cell-cell spread, including some not previously evaluated for inhibition of this mode of HIV-1 transmission. We found that three CD4 binding site antibodies, one from an immunised llama (J3) and two isolated from HIV-1-positive patients (VRC01 and HJ16) neutralised cell-cell spread between T cells, while antibodies specific for glycan moieties (2G12, PG9, PG16) and the MPER (2F5) displayed variable efficacy. Notably, while J3 displayed a high level of potency during cell-cell spread we found that the small size of the llama heavy chain-only variable region (VHH) J3 is not required for efficient neutralisation since recombinant J3 containing a full-length human heavy chain Fc domain was significantly more potent. J3 and J3-Fc also neutralised cell-cell spread of HIV-1 from primary macrophages to CD4+ T cells.
  
  
  CONCLUSIONS
  In conclusion, while bNabs display variable efficacy at preventing cell-cell spread of HIV-1, we find that some CD4 binding site antibodies can inhibit this mode of HIV-1 dissemination and identify the recently described llama antibody J3 as a particularly potent inhibitor. Effective neutralisation of cell-cell spread between physiologically relevant cell types by J3 and J3-Fc supports the development of VHH J3 nanobodies for therapeutic or prophylactic applications.
authors.forename: Laura E
authors.initials: LE
authors.lastname: McCoy
authors.forename: Elisabetta
authors.initials: E
authors.lastname: Groppelli
authors.forename: Christophe
authors.initials: C
authors.lastname: Blanchetot
authors.forename: Hans
authors.initials: H
authors.lastname: de Haard
authors.forename: Theo
authors.initials: T
authors.lastname: Verrips
authors.forename: Lucy
authors.initials: L
authors.lastname: Rutten
authors.forename: Robin A
authors.initials: RA
authors.lastname: Weiss
authors.forename: Clare
authors.initials: C
authors.lastname: Jolly
mesh_terms: D000818:Animals; D057134:Antibodies, Neutralizing / Q000276:immunology*; D015704:CD4 Antigens / Q000378:metabolism; D002161:Camelids, New World; D015483:HIV Antibodies / Q000276:immunology*; D015658:HIV Infections / Q000517:prevention & control* / Q000635:transmission; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D008264:Macrophages / Q000821:virology; D060888:Real-Time Polymerase Chain Reaction; D013601:T-Lymphocytes / Q000821:virology*
chemical_list: D057134:Antibodies, Neutralizing; D015704:CD4 Antigens; D015483:HIV Antibodies